Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients

R. Zachary Thompson, Craig A. Martin, Donna R. Burgess, W. Cliff Rutter, David S. Burgess

Research output: Contribution to journalArticle

3 Scopus citations


Background: Patients with cystic fibrosis (CF) exhibit increased clearance of beta-lactams. The purpose of this study was to predict the probability of beta-lactam target attainment (PTA) against Pseudomonas aeruginosa in adult CF patients based on local microbiological data. Methods: CF-specific pharmacokinetic parameters were obtained from published data for aztreonam, cefepime, ceftazidime, meropenem and piperacillin-tazobactam. Pharmacodynamic modeling was used to determine the PTA for bolus, prolonged infusion, and continuous infusion regimens. Results: Prolonged infusion of meropenem 2. g every 8. h performed the best among all regimens tested, with a PTA of 83%. The PTA was increased with both prolonged and continuous infusion; however, no regimen reached the target PTA of >. 90% against P. aeruginosa in CF patients at our institution. Conclusions: Prolonged and continuous infusion provided higher PTA than bolus for all regimens. Further investigation of novel regimens in CF patients is needed.

Original languageEnglish (US)
JournalJournal of Cystic Fibrosis
StateAccepted/In press - Nov 5 2015
Externally publishedYes


  • Beta-lactam
  • Continuous-infusion
  • Pharmacodynamics
  • Pharmacokinetics
  • Prolonged infusion
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients'. Together they form a unique fingerprint.

Cite this